Abstract
Permeation enhancers (PEs) are excipients used in oral biotherapeutic formulations to facilitate the transport of bioactive compounds across the intestinal barrier and prevent their degradation. Concerns associated with the chronic use of PEs demand comprehensive approaches to elucidate potential toxicity mechanisms. A recent publication from our group reported nephrotoxicity in beagles after daily administration of enteric-coated (EC) tablets containing propyl gallate (PG) as PE. To further characterize EC-PG mediated nephrotoxicity mechanisms, we conducted a longitudinal mass spectrometry (MS)-based multi-omics analysis of dog plasma lipidome and proteome. Time-course analyses revealed elevation across multiple lipid classes and in particular species containing arachidonic acid, which may reflect EC-PG treatment-induced inflammation. At the protein level, alterations in biological processes associated with coagulation, complement activation, protein degradation and metabolism, and lipid transport and metabolism were observed. Integrative multi-omics analyses provided additional insight into toxicity mechanisms at the interface of lipids and proteins. This holistic approach highlighted lipid transport and metabolism, oxidative stress, and inflammation as altered biological processes by EC-PG administration. Altogether, longitudinal multi-omics profiling and integrative analysis provided additional mechanistic hypotheses of EC-PG induced renal toxicity demonstrating the value of such approach to investigate mechanisms relevant to drug safety.
Supplementary materials
Title
Table S1
Description
Tablets composition and target dose levels per group.
Actions
Title
Table S2
Description
High level tablets composition and nephropathy status and grades per group.
Actions
Title
Table S3
Description
Urinary neutrophil gelatinase-associated lipocalin (NGAL) concentrations (ng/mL) and NGAL:creatinine ratios.
Actions
Title
Table S4
Description
Lipids concentration (nmol/mL) and results from linear mixed effect models. Lipid classes marked with an asterisk are reported in MS intensity.
Actions
Title
Table S5
Description
Proteins abundance (MS intensity) and results from linear mixed effect models.
Actions
Title
Table S6
Description
Weighted gene correlation network analysis (WGCNA) results.
Actions
Title
Supplementary Figure 1
Description
Principal component analysis of (A) lipidomics and (B) proteomics samples of no EC-PG (groups 3, 6 and 7) and EC-PG (groups 1, 2, 4 and 5) treated animals. The quality control samples (QC) clustered together indicating good technical reproducibility. The study samples from each group (No EC-PG and EC-PG) were intermixed suggesting limited effect of other excipients.
Actions